#MSI-H)
Dostarlimab monotherapy achieves 68% clinical complete response in previously untreated dMMR/MSI-H locally advanced rectal cancer, redefining treatment potential.

by Cercek A, Bachet JB (...) Roodhart JML et 32 al. in Ann Oncol #MedSky

👉 get more here

📖 read the article: here
November 3, 2026 at 9:47 AM
🚨 Wild AM5 motherboard deal: $169.99 at Walmart

$90 less than B&H and $90 less than Newegg.

• MSI MAG X870E Gaming Max WiFi, USB4 40Gbps
• Wi-Fi 7, 5Gb Ethernet, three M.2 slots

https://www.walmart.com/ip/19563972752
November 2, 2026 at 6:46 PM
Manche Rektumkrebspatienten mit bestimmten Tumormerkmalen könnten auf Chemo, Bestrahlung und OP verzichten: Die FDA hat eine Immuntherapie beschleunigt zugelassen.
FDA lässt Dostarlimab bei Rektumkarzinom-Subtyp zu
Die US-Arzneimittelbehörde FDA hat Dostarlimab (Jemperli) beschleunigt für Erwachsene mit lokal fortgeschrittenem Rektumkarzinom im Stadium II/III mit durch einen von der FDA autorisierten Test nachgewiesenem MSI-H- oder dMMR-Status zugelassen, was m
denkstrom.org
October 29, 2026 at 6:16 PM
🧬 Can dual checkpoint inhibition redefine the treatment landscape in MSI-H/dMMR metastatic colorectal cancer?

www.annalsofoncology.org/article/S092...

📊 Final CheckMate 8HW results demonstrate:
🔹 OS benefit vs nivolumab across all treatment lines
🔹 OS benefit vs chemotherapy in 1L (HR 0.37)
November 2, 2026 at 1:29 PM
#ESMO26: Dostarlimab monotherapy produced high rates of clinical complete response in patients with mismatch repair deficient (#dMMR)/microsatellite-high (#MSI-H) locally advanced #RectalCancer in the phase II AZUR-1 trial

🔗 https://ow.ly/iizM5100ny7

#InsightsbyESMO #immunotherapy
October 27, 2026 at 11:00 AM
Sara Lonardi, MD, discusses the final OS analysis of #CheckMate8HW from #ESMO26 and why nivolumab/ipilimumab should be offered to nearly all patients with MSI-H/dMMR mCRC. Read the full interview from Targeted Onc: www.targetedonc.com/view/lonardi...
October 31, 2026 at 9:24 PM
Clinical Complete Response with Dostarlimab Monotherapy in dMMR/MSI-H Locally Advanced Rectal Cancer: First Results from the Global AZUR-1 Trial. www.sciencedirect.com/science/arti... #hvhebron #onco [Text complet]
www.sciencedirect.com
October 29, 2026 at 10:21 AM
GSK has announced that it has secured U.S. approval for dostarlimab (Jemperli) as the first and only immunotherapy for adults with stage II or III microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) locally advanced rectal cancer.

See more👇
thepharmanavigator.com/news/gsk-win...
GSK Wins FDA Approval for its Locally Advanced Rectal Cancer Immunotherapy - The Pharma Navigator
The accelerated approval of dostarlimab (Jemperli) could allow eligible patients with biomarker-defined rectal cancer to avoid chemotherapy, radiotherapy, and surgery.
thepharmanavigator.com
November 2, 2026 at 1:32 PM
Sara Lonardi, MD, on final overall survival from CheckMate 8HW: nivolumab + ipilimumab vs. nivolumab or chemotherapy in MSI-H/dMMR metastatic colorectal cancer. #ESMO26

Watch now: https://bit.ly/4zd51ty
October 26, 2026 at 5:37 PM
Andrea Cercek, MD, on first results from the global registrational AZUR-1 trial: clinical complete response with dostarlimab alone in dMMR/MSI-H locally advanced rectal cancer. #ESMO26

Watch now: https://bit.ly/4eOJDCv
October 26, 2026 at 5:36 PM
AZUR-1: Dostarlimab alone achieved 68% sustained complete response at 12 months in dMMR/MSI-H locally advanced rectal cancer. Could IO spare patients chemo, radiotherapy & surgery? Watch here👉https://ow.ly/hBAx5100VhW @MeredithPelster @SCRIOncology #ESMO26 #RectalCancer
Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer - ecancer
Dr Meredith Pelster speaks to ecancer about the first results from the global registrational AZUR-1 trial, which evaluated dostarlimab monotherapy in patients w
ow.ly
October 26, 2026 at 11:59 AM
GSK trial data backs recent US approval of Jemperli for rectal cancer
GSK trial data backs recent US approval of Jemperli for rectal cancer
GSK (LSE:GSK) on Monday announced that interim results from its phase II AZUR-1 trial show that 76% of evaluable patients with stage II and III MSI-H/dMMR…
dlvr.it
October 26, 2026 at 6:24 PM
First interim analysis of GERCOR-GONO DEWI phase 2 study of watch-and-wait strategy for #dostarlimab in patients with localized dMMR/MSI-H #gastric #GEJ cancer presented today at #ESMO26
#ESMOAmbassadors @myesmo.bsky.social
#ESMO26: Phase II data suggest selected patients with localised gastro-oesophageal adenocarcinoma (#GEA) may benefit from a dostarlimab watch-and-wait strategy that can achieve good responses without surgery
🔗 https://ow.ly/Mu2w50ZZiKG

#InsightsbyESMO #GICancers
October 23, 2026 at 5:35 PM
Tumor testing matters: FDA grants accelerated approval to dostarlimab for adults with untreated stage II/III dMMR/MSI-H rectal cancer.
www.fda.gov/news-events/...
October 21, 2026 at 3:15 PM
酢酸や酪酸にも、MSS型大腸がんで免疫療法の効果を高める可能性を示した研究がある😊

一方で、酢酸をがん細胞が増殖に利用するという研究もあるらしい😨
ただし、こちらは細胞内部の酢酸代謝が重要な可能性があり、「お酢を控えましょう」という話にはならないようです。

個人的には、コリバクチンの研究にも期待したいところ。
またドスタルリマブも米国で直腸がんへの新たな適応が承認されましたが、対象はMSI-H/dMMRと適応が一部。やっぱり大腸がんそのものを避けたい。。😭

pmc.ncbi.nlm.nih.gov/articles/PMC...
ACSS2 is required for colorectal cancer progression and a druggable target for colorectal cancer treatment
Acyl-CoA synthetase short chain family member 2 (ACSS2) catalyzes the conversion of acetate to acetyl-CoA. Here we show that ACSS2 expression is markedly elevated in all stages of human colorectal can...
pmc.ncbi.nlm.nih.gov
October 26, 2026 at 2:52 PM
Dostarlimab FDA-approved for Stage II/III locally advanced MSI-H/dMMR rectal cancer #Medsky #oncsky www.fda.gov/drugs/resour...
FDA grants accelerated approval to dostarlimab for locally advanced re
Oncology Burst: FDA grants accelerated approval to dostarlimab for locally advanced rectal cancer
www.fda.gov
October 22, 2026 at 1:43 PM
OncoAlert 4Sight Abstracts to be Presented at #ESMO26
Watch-and-Wait Strategy for Dostarlimab in Localized dMMR/MSI-H Gastroesophageal Adenocarcinoma: Results From the First Interim Analysis of the GERCOR-GONO DEWI Phase II Study
October 22, 2026 at 8:00 AM
FDA approved dostarlimab for MSI-H/dMMR rectal cancer, with 68% achieving complete clinical response at one year after nine infusions.
Save What Matters
Curate Feeds | Make Collections | Customize Email Briefs
briefly.co
October 21, 2026 at 5:02 PM
Per GSK's Oct 19 release, the accelerated approval covers stage II/III MSI-H/dMMR locally advanced rectal cancer. In AZUR-1, 68% of evaluable patients (98/144; 95% CI 60-76%) had a sustained clinical complete response at 12 months.
October 21, 2026 at 3:07 PM
MSI’s RTX 5060 gaming laptop with 16GB DDR5 is down to $1,249
NOW $250 OFF **MSI Cyborg A15 Gaming Laptop** View Deal Free time is limited, budgets are tight, so when you manage to carve out a bit of time for gaming, you should do it right. That can be tough if your gaming machine sucks, and upgrading has been hard this past year what with the massive price spikes on hardware. Right now, B&H is selling an MSI Cyborg A15 gaming laptop for $1,249, which is $250 off its MSRP—maybe not the most dramatic discount we’ve ever seen, but that’s a solid drop at a time when gaming laptop deals have all but dried up. Inside, you’ll find an eight-core AMD Ryzen 7 260 processor paired with 16GB of DDR5 memory and a 1TB SSD, a hardware combination that’s increasingly hard to get at an affordable price. But it’s the RTX 5060 that stands out here, bringing enough graphical power to enjoy your PC games at more than 30 FPS, assuming you’re okay gaming at 1080p and employing Nvidia’s DLSS features like frame generation. The IPS display goes up to 144Hz of refresh, so visuals will be smooth and responsive. Some caveats to note before you buy. It doesn’t 55 watt-hour battery isn’t huge, and it drains pretty fast when unplugged. This isn’t the best laptop if you’re going to be doing work on it and will be on the go for hours at a time. It also has only a single M.2 slot, so upgrading storage will involve replacement rather than adding a second stick. And the screen only has a 45% NTSC color gamut, so it won’t suffice for color-oriented creative work like photo editing, video grading, and graphic design. The MSI Cyborg A15 is a good value at $1,249 in late 2026. If your current laptop is on its last leg and may not make it to the next big sales event, consider grabbing it. Or keep shopping with our picks for the best gaming laptops and best budget gaming laptops under $1,000.
www.pcworld.com
October 21, 2026 at 4:49 PM